Samsung Medical Center research team analyzes infliximab treatment in 469 pediatric patients

Comparative study of first-time biologic users and switchers

"Personalized strategies reflecting treatment history are needed"

A recent study has found that in pediatric and adolescent Crohn’s disease patients, blood drug concentrations may vary depending on previous biologic treatments, even if the same medication is administered. This suggests that a patient's prior treatment history should be considered when determining the therapeutic drug target concentration for biologic therapies.


Pediatric Crohn's Disease: Blood Drug Concentrations Vary According to Prior Biologic Therapy History View original image

On October 1, Samsung Medical Center announced that the research team led by Professors Kim Mijin and Kwon Eiyoung from the Department of Pediatrics and Adolescent Medicine had published the results of their analysis on the effect of infliximab therapy and blood drug concentrations in pediatric and adolescent Crohn’s disease patients in the latest issue of the international journal ‘Inflammatory Bowel Diseases’.


Crohn’s disease is an intractable disorder characterized by chronic, recurrent inflammation of the intestines. When it develops in children or adolescents, not only does it cause abdominal pain, diarrhea, and weight loss, but it can also lead to delayed growth and decreased quality of life. Therefore, early suppression of inflammation and long-term maintenance of therapeutic effects are especially important in this population.


For moderate to severe Crohn’s disease, biologics such as adalimumab and infliximab are commonly used as key treatments. These drugs require a sustained blood concentration above a certain threshold to achieve therapeutic efficacy, so clinicians often measure drug levels in the blood to adjust dosage or dosing intervals accordingly. However, existing therapeutic target concentrations have mostly been established based on patients starting these medications for the first time, making it unclear whether the same standards can apply to those who have previously used other biologic agents.


The research team retrospectively analyzed 469 pediatric and adolescent Crohn’s disease patients treated with infliximab at Samsung Medical Center between January 2003 and August 2024. Both groups received concurrent azathioprine therapy. Of these, 372 patients used infliximab as their first biologic, while 97 had previously been treated with adalimumab and were switched to infliximab due to secondary loss of response without anti-drug antibodies. Secondary loss of response means that the medication was initially effective, but efficacy diminished over time.


Approximately one year after starting infliximab, the team evaluated intestinal mucosal status via endoscopy and compared the trough blood drug concentrations closest to the time of the examination. The treatment choice was not randomized but was determined by clinical judgment in actual medical practice.


After one year of infliximab therapy, the endoscopic remission rate was 61.3% (228 of 372 patients) in the first biologic group and 58.8% (57 of 97 patients) in the group switched from adalimumab. There was no statistically significant difference between the two groups. The results indicate that patients switched from adalimumab to infliximab can expect similar mucosal improvement as those who started with infliximab.


However, the study did find differences in blood concentrations of infliximab. The mean trough infliximab concentration at one year was 6.19 µg/mL in the first-use group, compared to 4.73 µg/mL in the switched group, a significantly lower level. Dose adjustments such as shortening the dosing interval were also more frequently performed in the switched group.


Notably, the optimal trough blood concentration threshold for predicting endoscopic remission differed between groups: 5.16 µg/mL for the first-use group versus 3.29 µg/mL for the group switched from adalimumab. These findings indicate that rather than applying a uniform drug concentration target to all patients, it is necessary to interpret the relationship between drug levels and therapeutic response differently depending on prior treatment history. However, the researchers stressed that these results do not mean that the target concentration should be lowered for patients using a second biologic.


Professor Kwon Eiyoung explained, “Despite lower blood drug concentrations, patients who were switched from adalimumab to infliximab had similar one-year endoscopic remission rates. This means that the relationship between drug concentration and therapeutic response may vary according to treatment history.” Professor Kwon further emphasized, “This does not mean that it is appropriate to apply a lower target concentration to patients on their second treatment agent by changing current guidelines.”



Professor Kim Mijin stated, “Since pediatric Crohn’s disease requires long-term treatment, it is crucial to consider the patient’s entire treatment history, not just their response to a single medication.” Kim continued, “A tailored treatment strategy that considers treatment history, inflammation markers, body mass index, and drug concentrations is needed for optimal management.”


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing